Sen. Richard Blumenthal Sells Shares of Oncology Institute, Inc. (NASDAQ:STLN)

Senator Richard Blumenthal (Democratic-Connecticut) recently sold part of their stake in Oncology Institute, Inc. (NASDAQ:STLN). In a filing disclosed on October 26th, the Senator disclosed that they had sold between $15,001 and $50,000 in Oncology Institute stock on September 18th.

Senator Richard Blumenthal also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/23/2026.
• Sold $15,001 – $50,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/22/2026.
• Sold $1,001 – $15,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/22/2026.
• Sold $1,001 – $15,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/18/2026.

Oncology Institute Price Performance

Shares of NASDAQ STLN opened at $6.59 on Wednesday. Oncology Institute, Inc. has a 12-month low of $2.32 and a 12-month high of $7.13. The firm’s 50 day simple moving average is $6.47.

Oncology Institute (NASDAQ:STLN) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.08) earnings per share for the quarter. The business had revenue of $161.28 million for the quarter, compared to analyst estimates of $152.80 million. Equities research analysts anticipate that Oncology Institute, Inc. will post -0.21 EPS for the current year.

Insiders Place Their Bets

In other news, major shareholder Jorey Chernett acquired 12,000 shares of the firm’s stock in a transaction that occurred on Friday, August 14th. The stock was purchased at an average cost of $6.54 per share, for a total transaction of $78,480.00. Following the completion of the acquisition, the insider directly owned 10,660,858 shares of the company’s stock, valued at $69,722,011.32. The trade was a 0.11% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Brad Hively sold 298,853 shares of Oncology Institute stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $6.51, for a total value of $1,945,533.03. Following the completion of the sale, the director owned 411,976 shares of the company’s stock, valued at $2,681,963.76. The trade was a 42.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Oncology Institute

A number of institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. purchased a new position in shares of Oncology Institute during the second quarter valued at approximately $25,787,000. State Street Corp purchased a new stake in shares of Oncology Institute in the 2nd quarter worth $8,432,000. Renaissance Technologies LLC lifted its holdings in shares of Oncology Institute by 25.1% in the 1st quarter. Renaissance Technologies LLC now owns 902,809 shares of the company’s stock worth $2,772,000 after buying an additional 180,909 shares during the period. FourWorld Capital Management LLC grew its position in shares of Oncology Institute by 30.4% during the 1st quarter. FourWorld Capital Management LLC now owns 499,196 shares of the company’s stock worth $1,533,000 after buying an additional 116,496 shares in the last quarter. Finally, Manatuck Hill Partners LLC bought a new position in shares of Oncology Institute during the 2nd quarter worth $2,444,000. Hedge funds and other institutional investors own 36.86% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Weiss Ratings began coverage on shares of Oncology Institute in a research report on Thursday, August 6th. They set a “sell (d-)” rating for the company. Needham & Company LLC raised their target price on Oncology Institute from $7.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, October 14th. Lake Street Capital assumed coverage on Oncology Institute in a research note on Monday, July 6th. They issued a “buy” rating and a $10.00 price objective on the stock. Finally, BTIG Research lifted their price objective on Oncology Institute from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Thursday, July 9th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

About Senator Blumenthal

Richard Blumenthal (Democratic Party) is a member of the U.S. Senate from Connecticut. He assumed office on January 3, 2011. His current term ends on January 3, 2029. Blumenthal (Democratic Party, Working Families Party) ran for re-election to the U.S. Senate to represent Connecticut. He won in the general election on November 8, 2022. Before his election to the Senate, Blumenthal had served as the Connecticut Attorney General since 1991. He served in the Connecticut State Senate from 1987 to 1991 and in the Connecticut House of Representatives from 1984 to 1987. As of a 2014 analysis of multiple outside rankings, Blumenthal is one of the most reliable Democratic votes, meaning he can be considered a safe vote for the Democratic Party in Congress.

Oncology Institute Company Profile

The Oncology Institute is a value-based oncology care company focused on delivering comprehensive cancer treatment and related services through community-based care settings. Its model is designed to support patients throughout the cancer-care journey while coordinating treatment among oncologists, primary-care providers, specialists and other healthcare professionals.

The company provides medical oncology and hematology services, cancer screening and diagnosis, treatment planning, chemotherapy and other infusion therapies, supportive care, survivorship services and care-management programs.